Search results for "Interferons"

showing 10 items of 92 documents

Double methylation of tRNA-U54 to 2′-O-methylthymidine (Tm) synergistically decreases immune response by Toll-like receptor 7

2018

Abstract Sensing of nucleic acids for molecular discrimination between self and non-self is a challenging task for the innate immune system. RNA acts as a potent stimulus for pattern recognition receptors including in particular human Toll-like receptor 7 (TLR7). Certain RNA modifications limit potentially harmful self-recognition of endogenous RNA. Previous studies had identified the 2′-O-methylation of guanosine 18 (Gm18) within tRNAs as an antagonist of TLR7 leading to an impaired immune response. However, human tRNALys3 was non-stimulatory despite lacking Gm18. To identify the underlying molecular principle, interferon responses of human peripheral blood mononuclear cells to differentia…

0301 basic medicineBiology[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMethylation03 medical and health sciencesRNA TransferInterferonNucleic Acids[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]RNA and RNA-protein complexesGeneticsmedicineHumansComputingMilieux_MISCELLANEOUSToll-like receptorInnate immune systemGuanosine030102 biochemistry & molecular biologyPattern recognition receptorRNA[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyTLR7Immunity InnateCell biology030104 developmental biologyToll-Like Receptor 7Transfer RNALeukocytes MononuclearNucleic acid[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]InterferonsHydrogenThymidinemedicine.drug
researchProduct

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.

2021

Abstract Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer and in 24 patients with primary HER2-positive breast cancer undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or fecal microbiota transplantation from antibiotic-treated donors. Modulation of the intestinal microbiota was reflected in tumors by impaired recruitment of CD4+ T cells and granzyme B–posi…

0301 basic medicineCD4-Positive T-LymphocytesCancer ResearchReceptor ErbB-2medicine.medical_treatmentGut floraGranzymesMice0302 clinical medicineAntineoplastic Agents ImmunologicalTrastuzumabTumor Microenvironmentskin and connective tissue diseasesNeoadjuvant therapybiologyFecal Microbiota TransplantationInterleukin-12Neoadjuvant TherapyAnti-Bacterial AgentsTreatment OutcomeOncology030220 oncology & carcinogenesisStreptomycinCytokinesGut microbiota trastuzumab breast cancerFemaleTaxoidsmedicine.drugBridged-Ring CompoundsBreast NeoplasmsSettore MED/08 - Anatomia PatologicaNitric Oxide03 medical and health sciencesImmune systemBreast cancerVancomycinmedicineAnimalsHumansCyclophosphamideImmunity Mucosalbusiness.industryLachnospiraceaeDendritic cellDendritic CellsTrastuzumabbiology.organism_classificationmedicine.diseaseGastrointestinal Microbiome030104 developmental biologyGranzymeDoxorubicinImmune Systembiology.proteinCancer researchInterferonsbusinessCancer research
researchProduct

Mimiviruses and the Human Interferon System: Viral Evasion of Classical Antiviral Activities, But Inhibition By a Novel Interferon-β Regulated Immuno…

2017

International audience; In this review we discuss the role of mimiviruses as potential human pathogens focusing on clinical and evolutionary evidence. We also propose a novel antiviral immunomodulatory pathway controlled by interferon-beta (IFN-beta) and mediated by immune-responsive gene 1 (IRG1) and itaconic acid, its product. Acanthamoeba polyphaga Mimivirus (APMV) was isolated from amoebae in a hospital while investigating a pneumonia outbreak. Mimivirus ubiquity and role as protist pathogens are well understood, and its putative status as a human pathogen has been gaining strength as more evidence is being found. The study of APMV and human cells interaction revealed that the virus is …

0301 basic medicineCarboxy-LyasesImmunologyHuman pathogenVirusImmunomodulation03 medical and health sciences[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInterferon βInterferonVirologymedicineAnimalsHumansGiant VirusGenetic Predisposition to DiseaseGeneMimivirusbiologyProteinsSuccinatesCell BiologyInterferon-betabiology.organism_classificationVirologyDNA Virus Infections3. Good health030104 developmental biologyAcanthamoeba polyphagaHost-Pathogen InteractionsInterferonsMimiviridaemedicine.drugSignal TransductionJournal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection

2016

Single-nucleotide polymorphisms near the interferon lambda 3 (IFNL3) gene predict outcomes to infection and anti-viral treatment in hepatitis C virus (HCV) infection. To identify IFNL3 genotype effects on peripheral blood, we collected phenotype data on 400 patients with genotype 1 chronic hepatitis C (CHC). The IFNL3 responder genotype predicted significantly lower white blood cells (WBCs), as well as lower absolute numbers of monocytes, neutrophils and lymphocytes for both rs8099917 and rs12979860. We sought to define the WBC subsets driving this association using flow cytometry of 67 untreated CHC individuals. Genotype-associated differences were seen in the ratio of CD4CD45RO+ to CD4CD4…

0301 basic medicineGenotypeTranscription FactorT-LymphocytesHepatitis C virusImmunologyHepacivirusBiologymedicine.disease_causeMonocyteMonocytesCohort Studies03 medical and health sciencesGeneticInterferonGenotypeGeneticsmedicineHumansGenetics (clinical)Whole bloodHepaciviruInterleukinsMonocyteGATA3Hepatitis CHepatitis C ChronicInterleukinViral Loadmedicine.diseaseFlow CytometryAntigens Differentiation3. Good healthKiller Cells Natural030104 developmental biologymedicine.anatomical_structureT-LymphocyteImmunologyOriginal ArticleInterferonsCohort StudieViral loadTranscription Factorsmedicine.drugHuman
researchProduct

Viral resistance in HCV infection.

2018

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review…

0301 basic medicineGenotypeTreatment outcomeDrug ResistanceDrug resistanceHepacivirusBiologyViral resistanceAntiviral AgentsVirological response03 medical and health sciences0302 clinical medicinePharmacotherapyDrug TherapyDrug Resistance Multiple ViralVirologyRibavirinmedicineHumansGenetic variabilityViralTreatment FailureChronicAntiviral Agents; Drug Therapy Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance Multiple ViralGenetic VariationHepatitis CHepatitis C Chronicmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis C030104 developmental biologyHCVImmunologyCombinationHcv treatment030211 gastroenterology & hepatologyDrug Therapy CombinationInterferonsMultipleCurrent opinion in virology
researchProduct

Regulation of kynurenine biosynthesis during influenza virus infection.

2017

Influenza A viruses (IAVs) remain serious threats to public health because of the shortage of effective means of control. Developing more effective virus control modalities requires better understanding of virus–host interactions. It has previously been shown that IAV induces the production of kynurenine, which suppresses T-cell responses, enhances pain hypersensitivity and disturbs behaviour in infected animals. However, the regulation of kynurenine biosynthesis during IAV infection remains elusive. Here we showed that IAV infection induced expression of interferons (IFNs), which upregulated production of indoleamine-2,3-dioxygenase (IDO1), which catalysed the kynurenine biosynthesis. Furt…

0301 basic medicineIndoleshost-pathogen interactionViral Nonstructural Proteinsmedicine.disease_causeVirus ReplicationBiochemistryinfluenza viruschemistry.chemical_compoundMiceInfluenza A Virus H1N1 SubtypeInterferonOximesinnate immunityLungOxazolesKynurenineRegulation of gene expressionMice Inbred BALB CSulfonamidesTryptophaninterferon3. Good healthHost-Pathogen InteractionsFemaleMetabolic Networks and Pathwaysmedicine.drugHost–pathogen interaction030106 microbiologyPrimary Cell CultureBiologyta3111Antiviral AgentsVirus03 medical and health sciences3-dioxygenase (IDO1)Orthomyxoviridae InfectionsmedicineAnimalsHumansImmunologic FactorsIndoleamine-Pyrrole 23-DioxygenasePyrrolesMolecular BiologyInnate immune systemta1184Macrophagesta1183ta1182Cell BiologyVirologyindoleamine-pyrrole 2Thiazoles030104 developmental biologyHerpes simplex virusViral replicationchemistryGene Expression RegulationInterferonsTranscriptomeKynurenineThe FEBS journal
researchProduct

Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity

2016

Background The association between leptin and complement in hepatitis C virus (HCV) infection remains unknown. Methods A prospective study was conducted including 474 (250 genotype 1, 224 genotype 2) consecutive chronic hepatitis C (CHC) patients who had completed an anti-HCV therapy course and undergone pre-therapy and 24-week post-therapy assessments of interferon λ3-rs12979860 and HCV RNA/genotypes, anthropometric measurements, metabolic and liver profiles, and complement component 3 (C3), C4, and leptin levels. Results Of the 474 patients, 395 had a sustained virological response (SVR). Pre-therapy leptin levels did not differ between patients with and without an SVR. Univariate and mul…

0301 basic medicineLeptinRNA virusesMaleSteatosisSustained Virologic ResponsePhysiologyPeptide Hormoneslcsh:MedicineAminotransferasesHepacivirusmedicine.disease_causeGastroenterologyBiochemistryBody Mass IndexCytopathologychemistry.chemical_compoundMathematical and Statistical TechniquesHomeostasisProspective Studieslcsh:SciencePathology and laboratory medicineMultidisciplinaryComplement component 3Hepatitis C virusLeptinAlanine TransaminaseComplement C4Hepatitis CComplement C3Medical microbiologyMiddle AgedLipidsEnzymesmedicine.anatomical_structureCholesterolVirusesPhysical SciencesRNA ViralFemaleViral ClearancePathogensStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyGenotypeHepatitis C virusResearch and Analysis MethodsMicrobiologyAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesTransferasesWhite blood cellInternal medicineVirologymedicineHumansStatistical MethodsAgedMedicine and health sciencesFlavivirusesCholesterolbusiness.industryInterleukinslcsh:ROrganismsViral pathogensBiology and Life SciencesProteinsComplement System ProteinsHepatitis C Chronicmedicine.diseaseHormonesHepatitis virusesMicrobial pathogens030104 developmental biologychemistryAnatomical PathologyImmunologyMultivariate AnalysisEnzymologylcsh:QInterferonsSteatosisbusinessPhysiological ProcessesBody mass indexMathematicsViral Transmission and InfectionPLoS ONE
researchProduct

TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C

2016

Background & Aims We tested the putative association of the rs58542926 variant of TM6SF2, a recently described genetic determinant of nonalcoholic fatty liver disease, with steatosis and fibrosis in genotype 1(G1) chronic hepatitis C(CHC) patients. Methods A total of 694 consecutively biopsied Caucasian G1 CHC patients were genotyped for TM6SF2 rs58542926, IL28B rs12979860 and PNPLA3 rs738409. Steatosis was classified as absent (<5%), mild-moderate(5–29%) and severe(≥30%), Fibrosis was considered severe if=F3-F4. Results Carriers of TM6SF2 rs58542926 (6.3% of patients) exhibited lower serum levels of cholesterol (P = 0.04) and triglycerides (P = 0.01), but a similar distribution of steatosi…

0301 basic medicineLiver CirrhosisMalesteatosiIL28BStatistics as TopicGastroenterologySeverity of Illness IndexCohort Studies0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseMembrane ProteinFatty liverHepatitis CMiddle AgedItalyLiver030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLiver Cirrhosisteatosis; CHC; IL28B; PNPLA3; TM6SF2; Adult; Cohort Studies; Female; Hepatitis C Chronic; Humans; Interleukins; Italy; Lipase; Liver; Male; Membrane Proteins; Middle Aged; Severity of Illness Index; Statistics as Topic; Fatty Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; HepatologyTM6SF203 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansPNPLA3Hepatologybusiness.industryInterleukinsMembrane ProteinsOdds ratioLipaseHepatologyHepatitis C ChronicInterleukinmedicine.diseaseFatty LiverCHC030104 developmental biologyEndocrinologyInterferonsSteatosisCohort Studiebusiness
researchProduct

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis…

2019

Wong, Grace LH/0000-0002-2863-9389; Wong, Vincent WS/0000-0003-2215-9410; Mangia, A/0000-0002-2600-3555; Brahmania, Mayur/0000-0002-4671-1479; Chan, Henry Lik-Yuen/0000-0002-7790-1611; Brouwer, Willem Pieter/0000-0001-8713-1481; Feld, Jordan/0000-0003-2640-2211; Tanwandee, Tawesak/0000-0001-7634-0843; Jaroszewicz, Jerzy/0000-0003-0139-4753; Chuaypen, Natthaya/0000-0002-5415-510X

0301 basic medicineMicrobiology (medical)AdultMaleHBsAgHepatitis B virusSettore MED/09 - Medicina InternaGenotyping TechniquesGenome-wide association studymedicine.disease_causePeripheral blood mononuclear cellAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicSDG 3 - Good Health and Well-beingPegylated interferonInterferonmedicineHumansGWASchronic hepatitis BgeneticsProspective StudiespeginterferonArticles and CommentariesHepatitis B virusresponsebusiness.industryInterleukinInterferon-alphaMiddle Aged3. Good health030104 developmental biologyInfectious DiseasesHBeAgImmunologyMultivariate Analysis030211 gastroenterology & hepatologyFemaleInterferonsbusinessmedicine.drugGenome-Wide Association StudyClinical Infectious Diseases
researchProduct